Literature DB >> 15099443

Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats.

Hiroki Konishi1, Masaki Sumi, Nobuhito Shibata, Kanji Takada, Tokuzo Minouchi, Akira Yamaji.   

Abstract

We examined the effects of high-dose methylprednisolone (MP) on the disposition of ciclosporin (CsA) and hepatic microsomal CYP3A activity using rats. Methylprednisolone sodium succinate (MPS), a prodrug of MP, was intravenously administered as repeated doses (66.3 mg kg(-1)) for 3 days or as a single dose. In MP-treated rats, a significant increase was observed in the total body clearance (CL(tot)) and elimination rate constant (Ke) of intravenously administered CsA. The enzyme activities of triazolam hydroxylations and erythromycin N-demethylation in hepatic microsomes were also enhanced by about 50% by MP treatment, suggesting that the alteration in the CsA pharmacokinetics was due to significant induction of the hepatic CYP3A responsible for the metabolic conversion of CsA. In contrast, no significant changes in the values of CL(tot) and Ke were found following a single treatment with MP. On the other hand, MP inhibited the CYP3A-mediated triazolam hydroxylations in a concentration-dependent manner. The difference between the in-vivo and in-vitro inhibitory behaviours of MP was attributed to the rapid elimination of MP after biotransformation from MPS because the plasma MP concentration decreased with a half-life of 15 min immediately after reaching a level close to the inhibition constant for the triazolam 4-hydroxylation reaction (32.4 microM). Although there is a general consideration that MP cannot act as an enzyme inducer at maintenance doses, the present results strongly suggest that high-dose MP is likely to interact pharmacokinetically with CsA by inducing hepatic CYP3A. These results may provide basic explanations for the clinical experience that blood CsA levels are reduced during MP pulse therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15099443     DOI: 10.1211/0022357023114

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  4 in total

1.  Population pharmacokinetics of cyclosporine A in Japanese renal transplant patients: comprehensive analysis in a single center.

Authors:  Akira Okada; Hidetaka Ushigome; Misaki Kanamori; Aya Morikochi; Hidefumi Kasai; Tadashi Kosaka; Takatoshi Kokuhu; Asako Nishimura; Nobuhito Shibata; Keizo Fukushima; Norio Yoshimura; Nobuyuki Sugioka
Journal:  Eur J Clin Pharmacol       Date:  2017-06-15       Impact factor: 2.953

2.  Explaining variability in ciclosporin exposure in adult kidney transplant recipients.

Authors:  Rogier R Press; Bart A Ploeger; Jan den Hartigh; T van der Straaten; Hans van Pelt; Meindert Danhof; Hans de Fijter; Henk-Jan Guchelaar
Journal:  Eur J Clin Pharmacol       Date:  2010-03-31       Impact factor: 2.953

3.  Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.

Authors:  Julie C Lauffenburger; Christina L Mayer; Roy L Hawke; Kim L R Brouwer; Michael W Fried; Joel F Farley
Journal:  Eur J Gastroenterol Hepatol       Date:  2014-10       Impact factor: 2.566

4.  The Glomerular Filtration Rate Estimators in the Pharmacokinetic Modelling in Acute Kidney Injury: An Observational Study.

Authors:  Silvijus Abramavicius; Vaidotas Galaune; Agile Tunaityte; Astra Vitkauskiene; Gintautas Gumbrevicius; Aurelija Radzeviciene; Romaldas Maciulaitis
Journal:  Antibiotics (Basel)       Date:  2021-02-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.